RxDoctor Payments Data

Gregory Esselman, MD

Otolaryngology/Facial Plastic Surgery · Aiken, SCNPI 1265479000

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.2% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Optinose US, Inc. at 46.1% of the total. 2025 is the largest year on record at $237, 2.7 times the $89 reported in 2019.

$822in general payments, 2019–2025

Across 41 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$379
  • Regeneron Healthcare Solutions, Inc.$116
  • Sanofi$99
  • GSK$89
  • Merck$31
  • Kaleo, Inc.$30
  • plus $79 from 5 others

What the payments were for

  • Food & beverage$76693%
  • Education$567%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few otolaryngology/facial plastic surgery providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$332,543
Medicare patients
1,179
Services billed
9,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate12$7,071
Ipratropium Bromide145$3,867
Epinephrine15$1,985
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc25$1,088
Azelastine Hcl24$721
Ofloxacin17$651
Fluticasone Propionate21$440
Albuterol Sulfate HfaAlbuterol Sulfate27$432
Montelukast Sodium27$404
Methylprednisolone63$366
Azithromycin49$309
Amoxicillin56$262
Omeprazole24$217
Famotidine11$191
Mupirocin25$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$379$7,07112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few otolaryngology/facial plastic surgery providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other otolaryngology/facial plastic surgery in Aiken

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →